Pulse Biosciences has officially concluded patient enrollment for its pivotal **PRECISE-BTN clinical study**. This investigation evaluates the safety and clinical efficacy of the **nPulse Vybrance Percutaneous Electrode System**, a novel medical technology designed for the minimally invasive treatment of **symptomatic benign thyroid nodules**.
The study represents a significant milestone for the company’s **nanosecond Pulsed Field Ablation (nsPFA)** platform. By targeting the precise cellular structures of **thyroid nodules** without the traditional reliance on thermal energy, the **Vybrance system** aims to provide a reliable alternative to standard surgical interventions or radiofrequency ablation.
The **PRECISE-BTN trial** focuses on patients experiencing pressure symptoms or aesthetic concerns caused by non-cancerous thyroid growths. Researchers are closely monitoring the system’s ability to reduce nodule volume while maintaining the structural integrity of surrounding critical tissues, such as the **recurrent laryngeal nerve**. Because **nsPFA** utilizes ultra-short, high-voltage pulses to induce **non-thermal cell death**, it may offer a safer profile regarding nerve preservation compared to heat-based modalities.
“Completing enrollment is a testament to the collaborative efforts of our clinical investigators and the potential of our proprietary **nanosecond pulse technology**,” stated a spokesperson for the clinical program. The data gathered from this cohort will be essential for future regulatory submissions, including potential **FDA 510(k) clearance** or **PMA (Premarket Approval)** pathways, depending on the final risk-benefit analysis.
**Benign thyroid nodules** are highly prevalent, often leading to significant patient discomfort, difficulty swallowing, or hoarseness. Current treatment options frequently involve **thyroidectomy**, which carries risks of hypothyroidism and surgical complications. The **Vybrance Percutaneous Electrode System** is positioned as an office-based procedure, potentially reducing the financial burden on healthcare systems and the recovery time for patients.
Following the enrollment phase, the study will transition into a longitudinal monitoring period. Researchers will track patient outcomes over several months to confirm the durability of the volume reduction and ensure no long-term adverse events occur. Industry experts are watching these results closely, as the success of the **Vybrance system** could establish a new standard of care in **interventional endocrinology**.
Pulse Biosciences intends to present the final findings at upcoming medical conferences and submit the data for peer-reviewed publication. This evidence will serve as the foundation for broader clinical adoption and the potential commercial rollout of the technology across specialized thyroid centers.
